

SUPPLEMENTARY REFERENCES

1. Nakai M, Yamamoto Y, Baba M, Suda G, Kubo A, Tokuchi Y, et al. Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. *Sci Rep* 2022;12:1449.
2. Pons M, Rodríguez-Tajes S, Esteban JI, Mariño Z, Vargas V, Lens S, et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. *J Hepatol* 2020;72:472-480.
3. Rinaldi L, Guarino M, Perrella A, Pafundi PC, Valente G, Fontanella L, et al. Role of liver stiffness measurement in predicting HCC occurrence in direct-acting antivirals setting: A real-life experience. *Dig Dis Sci* 2019;64:3013-3019.
4. Wang JH, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, et al. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. *Liver Int* 2016;36:1793-1799.
5. Liu YC, Cheng YT, Chen YC, Hsieh YC, Jeng WJ, Lin CY, et al. Comparing predictability of non-invasive tools for hepatocellular carcinoma in treated chronic hepatitis C patients. *Dig Dis Sci* 2023;68:323-332.
6. Kuo YH, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, et al. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus. *Kaohsiung J Med Sci* 2022;38:268-276.
7. Morisco F, Federico A, Marignani M, Cannavò M, Pontillo G, Guarino M, et al. Risk factors for liver decompensation and HCC in HCV-cirrhotic patients after DAAs: A multicenter prospective study. *Cancers (Basel)* 2021;13:3810.
8. Zou Y, Yue M, Jia L, Wang Y, Chen H, Wang Y, et al. Repeated measurement of FIB-4 to predict long-term risk of HCC development up to 10 years after SVR. *J Hepatocell Carcinoma* 2022;9:1433-1443.
9. Ideno N, Nozaki A, Chuma M, Ogushi K, Hara K, Moriya S, et al. Fib-4 index predicts prognosis after achievement of sustained virologic response following direct-acting antiviral treatment in patients with hepatitis C virus infection. *Eur J Gastroenterol Hepatol* 2023;35:219-226.
10. Kumada T, Toyoda H, Yasuda S, Tada T, Tanaka J. Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication. *Eur J Gastroenterol Hepatol* 2021;33(1S Suppl 1):e513-e521.
11. Azzi J, Dorival C, Cagnot C, Fontaine H, Lusivika-Nzinga C, Leroy V, et al. Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response. *Clin Res Hepatol Gastroenterol* 2022;46:101923.
12. Caviglia GP, Troshina G, Santaniello U, Rosati G, Bombaci F, Birolo G, et al. Long-term hepatocellular carcinoma development and predictive ability of non-invasive scoring systems in patients with HCV-related cirrhosis treated with direct-acting antivirals. *Cancers (Basel)* 2022;14:828.
13. Tada T, Kurosaki M, Tamaki N, Yasui Y, Mori N, Tsuji K, et al. A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response. *JGH Open* 2021;6:20-28.
14. Ampuero J, Carmona I, Sousa F, Rosales JM, López-Garrido Á, Casado M, et al. A 2-Step strategy combining FIB-4 with transient elastography and ultrasound predicted liver cancer after HCV cure. *Am J Gastroenterol* 2022;117:138-146.
15. Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, et al. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. *Aliment Pharmacol Ther* 2021;54:1340-1349.
16. Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, Higuchi N, et al. Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. *Hepatol Int* 2019;13:293-301.
17. Hiraoka A, Kumada T, Ogawa C, Kariyama K, Morita M, Nouse K, et al. Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis. *J Gastroenterol Hepatol* 2019;34:436-441.
18. Kramer JR, Cao Y, Li L, Smith D, Chhatwal J, El-Serag HB, et al. Longitudinal associations of risk factors and hepatocellular carcinoma in patients with cured hepatitis C virus infection. *Am J Gastroenterol* 2022;117:1834-1844.
19. Ogawa E, Takayama K, Hiramane S, Hayashi T, Toyoda K. Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. *Aliment Pharmacol Ther* 2020;52:866-876.
20. Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, et al. Change in fibrosis 4 index as predictor of high risk of incident hepatocellular carcinoma After eradication of hepatitis C virus. *Clin Infect Dis* 2021;73:e3349-e3354.
21. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement. *JAMA* 2018;319:388-396.